866-997-4948(US-Canada Toll Free)

Januvia (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 46 Pages


GlobalDatas pharmaceuticals report, Januvia (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Januvia sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Januvia including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Januvia including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Januvia in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14

4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type 1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Januvia 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 26
7.3.1 Monotherapy Trials 26
7.3.2 Combination Therapy Trials 26
7.4 Approval History of Januvia 30
7.5 Factors Affecting Sales of Januvia 30
7.5.1 First Mover Advantage 30
7.5.2 Superior Efficacy 30
7.5.3 Restricted First Line Use 30
7.5.4 Potential Benefits 30
7.5.5 Blackbox Warnings 30
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Estimates 32
7.7.1 Target Patient Pool for Januvia 32
7.7.2 Dosing 32
7.7.3 Market Penetration 32
7.7.4 Annual Cost of Therapy 33
7.7.5 Sales Estimates of Januvia 34

8 Type 2 Diabetes Market: Appendix 43
8.1 Market Definitions 43
8.2 List of Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Net Penetration of Drug 45
8.3.5 Net Annual Dosing 45
8.3.6 Annual Cost of Therapy 45
8.3.7 Primary Research 45
8.3.8 Expert Panels 45
8.4 Drug Sales Estimates Model 46
8.5 Contact Us 46
8.6 Disclaimer 46
8.7 Sources 46

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
Table 8: Diabetes Drugs Evolution
Table 9: Glycemic Parameters in 18-week and 24-week Placebo Controlled Studies of Januvia
Table 10: Results of Januvia as Add-on Combination Therapy with Metformin and Rosiglitazone
Table 11: Results of Januvia as Initial Combination Therapy with Metformin
Table 12: Results of Januvia as Add-on and Initial Combination Therapy with Pioglitazone
Table 13: Approval History of Januvia for Type 2 Diabetes by Indication
Table 14: Drug Risk Benefit Score of Januvia
Table 15: Annual Cost of Januvia for Type 2 Diabetes, 2011
Table 16: Januvia, Type 2 Diabetes, Global, Sales Estimates ($m), 2006-2020
Table 17: Januvia, Type 2 Diabetes, The US, Sales Estimates ($m), 2006-2020
Table 18: Januvia, Type 2 Diabetes, The UK, Sales Estimates ($m), 2007-2020
Table 19: Januvia, Type 2 Diabetes, France, Sales Estimates ($m), 2007-2020
Table 20: Januvia, Type 2 Diabetes, Germany, Sales Estimates ($m), 2007-2020
Table 21: Januvia, Type 2 Diabetes, Italy, Sales Estimates ($m), 2007-2020
Table 22: Januvia, Type 2 Diabetes, Spain, Sales Estimates ($m), 2007-2020
Table 23: Januvia, Type 2 Diabetes, Japan, Sales Estimates ($m), 2009-2020

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 12
Figure 6: Mechanism of Action of Sulfonylurea 18
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 19
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 20
Figure 9: Mechanism of Action of Thiazolidinediones 21
Figure 10: Mechanism of Action of DPP IV Inhibitors 22
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 23
Figure 12: Mechanism of Action of Januvia 24
Figure 13: Januvia, Type 2 Diabetes, Global, Sales Estimates ($m), 20062020 33
Figure 14: Januvia, Type 2 Diabetes, The US, Sales Estimates ($m), 20062020 34
Figure 15: Januvia, Type 2 Diabetes, The UK, Sales Estimates ($m), 20072020 35
Figure 16: Januvia, Type 2 Diabetes, France, Sales Estimates ($m), 20072020 36
Figure 17: Januvia, Type 2 Diabetes, Germany, Sales Estimates ($m), 20072020 37
Figure 18: Januvia, Type 2 Diabetes, Italy, Sales Estimates ($m), 20072020 38
Figure 19: Januvia, Type 2 Diabetes, Spain, Sales Estimates ($m), 20072020 39
Figure 20: Januvia, Type 2 Diabetes, Japan, Sales Estimates ($m), 20092020 40
Figure 21: Januvia, Type 2 Diabetes, Sales Distribution by Country (%), 2020 41

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *